Amgen Inc/ US0311621009 /
2024-04-18 10:15:00 PM | Chg. -1.3200 | Volume | Bid1:13:19 AM | Ask1:13:19 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
262.7500USD | -0.50% | 2.08 mill. Turnover: 343.03 mill. |
262.5800Bid Size: 200 | 263.0500Ask Size: 100 | 140.81 bill.USD | 3.29% | 20.92 |
GlobeNewswire
04-15
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
GlobeNewswire
04-15
Shah Capital nominates two highly qualified independent director candidates for Novavax
GlobeNewswire
04-08
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual ...
GlobeNewswire
04-08
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...
GlobeNewswire
04-05
CORRECTION -- NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US
GlobeNewswire
04-04
Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth
GlobeNewswire
04-03
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engag...
GlobeNewswire
03-25
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate ...
GlobeNewswire
03-25
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Director...
GlobeNewswire
03-20
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
GlobeNewswire
03-18
NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digita...
GlobeNewswire
03-18
Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D...
GlobeNewswire
03-18
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Col...